Pfizer Buys Fungal Therapies Maker Amplyx
Pfizer has acquired San Diego, Calif.-based Amplyx Pharmaceuticals, broadening its portfolio of potential therapies for treating drug-resistant fungal infections.
Under the deal, Pfizer gains access to Amplyx’s lead candidate, Fosmanogepix (APX001), a novel treatment for invasive fungal infections, as well as two early-stage candidates, an antiviral (MAU868) and another antifungal (APX2039).
Fosmanogepix is being evaluated in ongoing phase 2 trials in both intravenous and oral formulations for treatment of life-threatening fungal infections. Pfizer noted that no new antifungal therapies have been approved by the FDA in almost 20 years.
The financial terms of the purchase were not disclosed